NovaBridge Biosciences grants 254,780 options to counsel

NovaBridge Biosciences reported that General Counsel Lin Liwei Lorraine received a grant of 254,780 2025 Employee Share Options, each representing a right to buy American Depositary Shares at an exercise price of 1.9300 per ADS.

Rhea-AI Filing Summary

NovaBridge Biosciences reported that General Counsel Lin Liwei Lorraine received a grant of 254,780 2025 Employee Share Options, each representing a right to buy American Depositary Shares at an exercise price of 1.9300 per ADS. The options expire on 2036-07-08 and relate to an equivalent number of underlying Ordinary Shares represented by ADSs. The grant vests over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance in three equal annual installments thereafter.

Insights

Equity Compensation Analyst

Routine option grant to General Counsel, expanding long-term equity alignment.

The General Counsel of NovaBridge Biosciences received a compensation-related award of 254,780 employee share options at an exercise price of 1.9300 per ADS. This is coded as a grant/award acquisition, not an open-market purchase, so it primarily reflects equity-based pay rather than a discretionary investment decision.

The options vest over five years, with 40% vesting on the second anniversary of February 1, 2026 and the remainder in three equal annual installments, promoting multi-year retention. The options expire on 2036-07-08, giving a long window to exercise. Footnotes state the number of underlying securities and exercise price are expressed in terms of American Depositary Shares, and that each 10 ADSs represent 23 Ordinary Shares, clarifying the capital structure representation.

Insider Trade Summary

Grant/Award: 254,780 shares

Grant/Award 1 txn

Insider Lin Liwei Lorraine

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	2025 Employee Share Option (right to buy) F1, F2, F3	254,780	$0.00	$0.00

Holdings After Transaction: 2025 Employee Share Option (right to buy) — 254,780 contracts (Direct)

Footnotes (3)

1. F1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").
2. F2. The option vests and becomes exercisable over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance vesting in three equal annual installments thereafter.
3. F3. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Key Figures

Employee Share Options Granted: 254,780 options Exercise Price: 1.9300 per ADS Expiration Date: 2036-07-08 +3 more

6 metrics

Employee Share Options Granted 254,780 options 2025 Employee Share Option grant to General Counsel on 2026-07-08

Exercise Price 1.9300 per ADS Exercise price for 2025 Employee Share Option award

Expiration Date 2036-07-08 Expiration date of the 2025 Employee Share Options

Underlying Securities 254,780 Ordinary Shares Number of underlying Ordinary Shares represented by the options via ADSs

Initial Vesting Tranche 40% Portion of options vesting on the second anniversary of February 1, 2026

ADS to Ordinary Share Ratio 10 ADSs represent 23 Ordinary Shares Relationship between ADSs and Ordinary Shares stated in footnotes

Key Terms

American Depositary Shares ("ADS"), exercise price, vests and becomes exercisable, Ordinary Shares

4 terms

American Depositary Shares ("ADS") financial

"Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS")."

American depositary shares are U.S.-listed certificates issued by a bank that represent ownership in shares of a foreign company, trading on American exchanges in dollars. Think of them as voucher tickets that let U.S. investors buy and sell foreign stock without handling foreign exchanges, currencies, or settlement rules directly. They matter because they make cross-border investing simpler and can affect liquidity, dividend payments and currency exposure for investors.

exercise price financial

"Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS")."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable over five years, with 40% vesting..."

Ordinary Shares financial

"The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares..."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did NovaBridge Biosciences (NBP) grant to its General Counsel?

NovaBridge Biosciences granted its General Counsel 254,780 2025 Employee Share Options, each representing a right to buy ADSs at an exercise price of 1.9300 per ADS, expiring on 2036-07-08.

Is the NovaBridge Biosciences (NBP) Form 4 transaction a market purchase or a compensation grant?

The Form 4 reports a grant/award acquisition of employee share options, not an open-market purchase. It is coded as transaction code A, indicating a compensation-related award rather than a buy on the market.

What is the vesting schedule of the NovaBridge Biosciences (NBP) options granted?

The option vests over five years, with 40% vesting on the second anniversary of February 1, 2026 and the remaining 60% vesting in three equal annual installments thereafter, subject to continued service.

How many securities does the NovaBridge Biosciences (NBP) insider hold after the option grant?

Following the reported transaction, the insider holds 254,780 2025 Employee Share Options directly. These options correspond to an equivalent number of underlying Ordinary Shares represented by American Depositary Shares.

How are NovaBridge Biosciences (NBP) ADSs related to its Ordinary Shares in this Form 4?

The footnotes state that the number of underlying securities and exercise price are expressed in terms of ADSs, and that each 10 ADSs represent 23 Ordinary Shares, clarifying the ratio between the two share types.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Liwei Lorraine

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	$1.93(1)	07/08/2026		A		254,780(1)		(2)	07/08/2036	Ordinary Shares(3)	254,780(1)	$0	254,780(1)	D

Explanation of Responses:

1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").

2. The option vests and becomes exercisable over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance vesting in three equal annual installments thereafter.

3. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

	/s/ Kyler Lei as attorney-in-fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)